Advancing the global public health agenda for NAFLD: a consensus statement
Open accessThe DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease with a substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts develop consensus statements and recommendations addressing a broad range of topics on NAFLD to raise awareness and spur action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationExpanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Research works printed but not linked: 2
- Lazarus, J. V. et al. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge? Int. Liver Congr. 75 (Suppl. 2), 23–26 (2021).
- Grime, M. M. & Wright, G. in Wiley StatsRef: Statistics Reference Online 1–6 (Wiley, 2011).
Cited by
Items 201–300 of 807
Yu, Y., Yang, Y., Li, Q., Yuan, J., & Zha, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-96478-6 · Cited by 29
Dissayabutra, T., Chuaypen, N., Somnark, P., Boonkaew, B., Udomkarnjananun, S., Kittiskulnam, P., Charoenchittang, P., Prombutara, P., & Tangkijvanich, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-00237-6 · Cited by 27
Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study
Búzová, D., Braghini, M. R., Bianco, S. D., Re, O. L., Raffaele, M., Fröhlich, J., Kisheva, А., Crudele, A., Mosca, A., Sartorelli, M. R., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2082 · Cited by 27
“NAFLD prevalence has increased significantly in relation to the obesity prevalence.[1,2] Based on its link with obesity and other metabolic derangements, a new name has been proposed for NAFLD, which is metabolic associated fatty liver disease (MAFLD).”
BackgroundThe Dynamic Role of Endoplasmic Reticulum Stress in Chronic Liver Disease
Jackson, K. G., Way, G. W., Zeng, J., Lipp, M. K., & Zhou, H. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.03.009 · Cited by 25
“77 Another etiology of NAFLD, “ lean NAFLD, ” is closely connected with mutations in hepatic lipid metabolism genes.”
BackgroundShih, C., Wu, K., Hsieh, M., Yang, J., Chen, Y., Tsai, W., Chen, W., Liang, P., Wei, Y., Tsai, P., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10576-z · Cited by 25
“Despite the growing disease burden of NAFLD, there remains a significant gap in the awareness and knowledge of NAFLD among physicians and policy makers [4, 5].”
Self-citationMao, T., Sun, Y., Xu, X., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000234 · Cited by 27
“Driven partially by rising obesity levels, the global prevalence of NAFLD among adults, children, and adolescents has increased in the last few decades,[1] reaching 25% in 2016, with higher rates observed in South America, the Middle East, and Asia.”
BackgroundRetinol-binding protein-4 and nonalcoholic fatty liver disease
Huang, H., & Xu, C. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002135 · Cited by 27
“However, unlike other highly prevalent diseases, NAFLD has received little attention.([6]) The pathogenesis of NAFLD remains to be elucidated, and curative treatment remains to be explored.”
Meda, C., Dolce, A., Vegeto, E., Maggi, A. C., & Torre, S. D. (2022) · Nutrients · doi:10.3390/nu14163262 · Cited by 24
“Despite the growing public health impact of NAFLD [2], treatment options remain limited, probably as a consequence of the limited understanding of the biological drivers of the heterogeneity of NAFLD pathogenesis and progression [3,4].”
BackgroundNatural-Product-Mediated Autophagy in the Treatment of Various Liver Diseases
Fan, G., Li, F., Wang, P., Jin, X., & Liu, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315109 · Cited by 24
“It is characterized by the accumulation of a plethora of lipid droplets in hepatocytes and can progress from simple steatosis to steatohepatitis and subsequently to liver fibrosis, liver cirrhosis, and, eventually, devastating malignancies [4,5].”
BackgroundZhang, X., Zhi, Y., Zan, X., Fan, K., Chen, K., Zhao, S., Dai, X., Li, L., Yang, Y., Hu, K., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166656 · Cited by 25
Zhang, M., Tian, S. Y., Shuo, Y., Zhou, X., Zheng, X. H., Li, B., Guo, G. Y., Yu, J. H., Su, R. J., Yang, F. F., et al. (2023) · Liver International · doi:10.1111/liv.15547 · Cited by 23
Lopez-Escalera, S., Lund, M. L., Hermes, G. D. A., Choi, B. S.-Y., Sakamoto, K., & Wellejus, A. (2023) · Nutrients · doi:10.3390/nu15102361 · Cited by 23
“Therefore, there is an urgent need for novel approaches to manage this complex disease [1].”
BackgroundLiu, L., Geng, Y., & Xiong, C. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2255825 · Cited by 24
“Non-alcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated fatty liver disease (MAFLD), refers to the exclusion of alcohol and other definite liver damage factors (such as drugs), is a clinicopathological syndrome characterized by diffuse lipid droplet deposition in hepatocytes [1,5,8,27…”
BackgroundLi, Y., & Liu, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1361567 · Cited by 24
“Currently, no pharmaceuticals are specifically endorsed for the treatment of NAFLD, making lifestyle modification and the management of risk factors the foremost therapeutic approach for patients with NAFLD (8).”
BackgroundMustafa, A., Kite, C., Lagojda, L., Dallaway, A., Chatha, K. K., Than, N. N., Kassi, E. N., Kyrou, I., & Randeva, H. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311275 · Cited by 26
Zhao, Z., Zou, J., Huang, X., Fan, Y., & Wang, K. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.971913 · Cited by 24
“The MR analyses conform to three assumptions: (1) genetic variants are associated with the exposure; (2) genetic instruments are not associated with the outcome via confounders; (3) genetic instruments do not affect the outcome directly, only possibly via the exposure (Figure 1).”
BackgroundRobea, M. A., Balmuș, I.-M., Gîrleanu, I., Huiban, L., Muzica, C. M., Ciobica, A. S., Stanciu, C., Cimpoesu, C. D., & Trifan, A. V. (2023) · Medicina · doi:10.3390/medicina59091614 · Cited by 23
“In 2020, the estimation of the global prevalence of the disease was almost 2 billion cases, making NAFLD the most prevalent disease in human history [3].”
Allen, A. M., Pose, E., Reddy, K. R., Russo, M. W., & Kamath, P. S. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.11.007 · Cited by 24
Self-citationHu, J., Li, S., Zhong, X., Wei, Y., Sun, Q.-J., & Zhong, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25460 · Cited by 24
“NAFLD, which has a worldwide incidence of approximately 25 %, comprises subtypes, including simple fatty liver, non-alcoholic steatohepatitis (NASH), and cirrhosis [1 – 4].”
Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers
Hemminki, K., Sundquist, K., Sundquist, J., Försti, A., Liška, V., Hemminki, A., & Li, X. (2022) · International Journal of Cancer · doi:10.1002/ijc.34308 · Cited by 25
“NAFLD has bidirectional associations with diabetes and obesity related metabolic syndrome, all of which are an increasing global health concern.(12) In spite of the diversity of the risk factors for HCC, most of them share the mechanism of action through chronic inflammation, necroinflammation and the related immune d…”
BackgroundNAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
Chen, B. Y., Tang, W. H. W., Rodriguez, M., Corey, K. E., Sanyal, A. J., Kamath, P. S., Bozkurt, B., Virk, H. U. H., Pressman, G. S., Lazarus, J. V., et al. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1757712 · Cited by 24
Self-citationZhao, X., Xu, D. Z., Ji, W., Lu, Z., Huang, C., Zhao, J., Xiao, T., Wang, D., Kong, Y., Jia, J., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003726 · Cited by 21
“[10] Given this increasing impact, understanding the burden of NAFLD within the broader spectrum of CLD is crucial for local, regional, and global policymakers to develop targeted prevention and treatment strategies.”
DNA methylation in cell plasticity and malignant transformation in liver diseases
Kim, M., Delgado, E. R., & Ko, S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108334 · Cited by 21
It is time to expand the fatty liver disease community of practice
Lazarus, J. V., Kopka, C. J., Younossi, Z. M., & Allen, A. M. (2023) · Hepatology · doi:10.1097/hep.0000000000000411 · Cited by 21
“[9] There are a few educated guesses for why there is such a small CoP for fatty liver disease.”
BackgroundSelf-citationQin, T., Chen, X., Meng, J., Guo, Q., Xu, S., Hou, S., Yuan, Z., & Zhang, W. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2204349 · Cited by 22
“Unfortunately, liver diseases have brought wide-ranging social and economic burdens with morbidity and mortality worldwide, while effective treatments are still in need (Albhaisi, Bajaj, and Sanyal 2020; Lazarus et al. 2022).”
New discoveries in the field of metabolism by applying single-cell and spatial omics
Xie, B., Gao, D., Zhou, B., Chen, S., & Wang, L. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.06.002 · Cited by 26
Niture, S. K., Gadi, S. V., Qi, Q., Ríos-Colón, L., Khatiwada, S., Vandana, V., Fernando, R. A., Levine, K. E., & Kumar, D. (2023) · Toxins · doi:10.3390/toxins15070411 · Cited by 22
“NAFLD is a global chronic liver disease considered a major public health burden [32].”
BackgroundMedical Radiology: Current Progress
Pepe, A., Crimì, F., Vernuccio, F., Cabrelle, G., Lupi, A., Zanon, C., Gambato, S., Perazzolo, A., & Quaia, E. (2023) · Diagnostics · doi:10.3390/diagnostics13142439 · Cited by 21
“MRI-based tools, such as MRI-proton density fat fraction (PDFF), MR elastography, or MRI corrected T1, allow for the further risk stratification of NAFLD patients in whom other non-invasive tools are deemed indeterminate or not reflective of clinical suspicion [69,70].”
BackgroundMethodThrombospondin 2 is a key determinant of fibrogenesis in non‐alcoholic fatty liver disease
Kimura, T., Iwadare, T., Wakabayashi, S., Kuldeep, S., Nakajima, T., Yamazaki, T., Aomura, D., Zafar, H., Iwaya, M., Joshita, S., et al. (2023) · Liver International · doi:10.1111/liv.15792 · Cited by 22
“Non-alcoholic fatty liver disease (NAFLD) is a global health concern 1,2 that encompasses a spectrum of conditions, ranging from non-alcoholic fatty liver to non-alcoholic steatohepatitis (NASH).”
BackgroundMi, A., Hu, Q., Liu, Y., Zhao, Y., Shen, F., Lan, J., Lv, K., Wang, B., Gao, R., & Yu, X. (2023) · Food & Function · doi:10.1039/d3fo03572g · Cited by 21
Undiagnosed Cirrhosis and Hepatic Encephalopathy in a National Cohort of Veterans With Dementia
Bajaj, J. S., Silvey, S. G., Rogal, S. S., O’Leary, J. G., Patton, H. M., Morgan, T. R. M., Kanagalingam, G., Gentili, A., Godschalk, M., & Patel, N. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.53965 · Cited by 24
Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9
Xin, X., Chen, C., Xu, X., Lv, S., Sun, Q., An, Z., Chen, Y., Xiong, Z., Hu, Y., & Feng, Q. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103499 · Cited by 21
“Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a global liver disease, affecting nearly one-quarter of the adult population worldwide [1,2].”
Chen, J., Ruan, X., Sun, Y., Li, X., Yuan, S., & Larsson, S. C. (2022) · Nutrition · doi:10.1016/j.nut.2022.111910 · Cited by 22
Wu, W., Guo, Y., Li, Q., & Jia, C. (2024) · Liver International · doi:10.1111/liv.16112 · Cited by 22
“7,8 Despite its prevalence and risks, a substantial number of MASLD patients remain undiagnosed.”
Lim, T. W., Lim, R. L. H., Pui, L. P., Tan, C. P., & Ho, C. W. (2025) · Future Foods · doi:10.1016/j.fufo.2025.100562 · Cited by 27
Sleep Disorders: Pathogenesis and Therapeutic Interventions
Liu, C., He, Z., Wu, Y., Liu, Y., Li, Z., Jia, Y., & Xiang, H. (2025) · MedComm · doi:10.1002/mco2.70130 · Cited by 22
“NAFLD, a prevalent liver disease worldwide, is strongly linked to obesity, type 2 diabetes, hyper-lipidemia, sleep apnea, and a sedentary lifestyle [150–152].”
Self-citationGlobal burden of liver cirrhosis: trends from 1990–2021 and projections to 2060
Luo, X., He, Y., Zheng, J., & Liao, J. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01109-5 · Cited by 21
“However, currently no country in the world has formulated a written strategy for the prevention, management, and treatment of NAFLD [41].”
Lou, Z., Wang, R., Belmekki, B. E. Y., & Alouini, M. (2026) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00061-7 · Cited by 28
Moore, E., Patanwala, I., Jafari, A., Davies, I. G., Kirwan, R., Newson, L., Mazidi, M., & Lane, K. E. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad054 · Cited by 21
Sani, F., Zomorrod, M. S., Azarpira, N., & Soleimani, M. (2023) · Stem Cells International · doi:10.1155/2023/8836452 · Cited by 21
“The prevalence of NAFLD among the global adult population is about 23 % – 25 % , and it is the major cause of chronic liver disease and transplantation [6].”
RetractedZheng, M., Wang, X., Yin, Y., Chen, S., Guo, C., Wu, S., & Yu, Y. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100064 · Cited by 22
Self-citationPredicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach
Mouskeftara, T., Kalopitas, G., Liapikos, T., Arvanitakis, K., Germanidis, G. S., & Gika, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115965 · Cited by 20
Satthawiwat, N., Jinato, T., Sutheeworapong, S., Tanpowpong, N., Chuaypen, N., & Tangkijvanich, P. (2024) · Nutrients · doi:10.3390/nu16121800 · Cited by 20
“Accumulating evidence also indicates that MASLD is associated with increased risks of extrahepatic manifestations, namely cardiovascular disease (CVD), chronic kidney disease (CKD), and cancers [3].”
BackgroundNew avenues for NASH therapy by targeting ACC
Bian, H., Liu, Y.-M., & Chen, Z. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.001 · Cited by 20
Lazarus, J. V., Mark, H. E., Colombo, M. G., Demaio, S., Dillon, J. F., George, J., Hagström, H., HOCKING, S. L., Lee, N., Nieuwenhuijsen, M. J., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16720 · Cited by 20
Self-citationGellert‐Kristensen, H., Tybjærg‐Hansen, A., Nordestgaard, B. G., Ghouse, J., Fuchs, A., Kühl, J. T., Sigvardsen, P. E., Kofoed, K. F., & Stender, S. (2023) · Liver International · doi:10.1111/liv.15629 · Cited by 23
Castéra, L., Alazawi, W., Bugianesi, E., Caussy, C., Federici, M., Romero‐Gómez, M., Schattenberg, J. M., Basuroy, R., Prasad, P., Estulin, D., et al. (2025) · Liver International · doi:10.1111/liv.16224 · Cited by 20
Self-citationSarkoohi, Z., Bastan, M., Gharaei, M. A. K., Iranmanesh, M., Adinepour, A., Khajezade, R., Bahri, F., Akhlaghi, F., Kadkhodamanesh, A., Pourghadamyari, H., et al. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-00973-5 · Cited by 20
“Greater awareness and earlier detection strategies could improve epidemiological surveillance and public health response [8, 24].”
Zeng, J., Gu, C., Wen, C., & Shen, C. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02750-z · Cited by 21
“Despite MASLD's intricate associations with prevalent noncommunicable diseases (NCDs) and substantial overlap in public health management pathways, its exclusion from the World Health Organization's Global Action Plan for NCDs has perpetuated systemic neglect [10].”
Handelman, S. K., Puentes, Y., Kuppa, A., Chen, Y., Du, X., Feitosa, M. F., Palmer, N. D., & Speliotes, E. K. (2022) · Hepatology Communications · doi:10.1002/hep4.2066 · Cited by 19
“Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and has risen to a global prevalence ranging from 23% to 25%.[1] The hallmark of NAFLD is increased intrahepatic triglyceride accumulation (i.”
BackgroundJulián, M. T., Arteaga, Í., Torán‐Monserrat, P., Pera, G., de, A. P.-M., Ruiz-Rojano, I., Casademunt-Gras, E., Chacón, C., & Alonso, N. (2024) · Nutrients · doi:10.3390/nu16111586 · Cited by 20
“Nonalcoholic fatty liver disease (NAFLD) currently represents the most prevalent cause of chronic liver disease in the western world [1–3].”
BackgroundXuan, Y., Hu, W., Wang, Y., Li, J., Yang, L., Yu, S., & Zhou, D. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1427138 · Cited by 19
Iruzubieta, P., Mayo, R., Mincholé, I., Martínez‐Arranz, I., Arias‐Loste, M. T., Ibáñez, L., Ampuero, J., Abad, J., Martín‐Mateos, R., Laso, A. B. F., et al. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12589 · Cited by 21
“4 Early identification of high ‐ risk patients for effective disease management has likely the potential to decrease overall mortality.”
BackgroundSelf-citationPCPE-1, a brown adipose tissue-derived cytokine, promotes obesity-induced liver fibrosis
Hsiao, Y., Yoshida, Y., Okuda, S., Abe, M., Mizuno, S., Takahashi, S., Nakagami, H., Morishita, R., Kamimura, K., Terai, S., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00196-0 · Cited by 19
“As MASH is expected to supercede hepatitis B or C as the leading cause of cirrhosis, it is becoming urgent to explore druggable targets for this critical disorder (Lazarus et al, 2022).”
BackgroundNasr, P., Shang, Y., Wester, A., Strandberg, R., Widman, L., Lazarus, J. V., & Hagström, H. (2024) · Liver International · doi:10.1111/liv.16091 · Cited by 20
“24 For example, a community screening initiative for MASLD with increased liver stiffness may, based on our results, be more valuable in areas with lower education, a higher prevalence of immigrants and a higher proportion of single households, which may have different health-seeking patterns and…”
Self-citationFan, Z., Ma, W.-J., Zhang, W., Li, H., Zhai, J., Zhao, T., Guo, X., Sinclair, A. J., & Li, D. (2022) · Food & Function · doi:10.1039/d2fo02349k · Cited by 19
Han, N., He, J., Shi, L., Zhang, M., Zheng, J., & Fan, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1020899 · Cited by 23
“NAFLD is a liver disease associated with obesity, insulin resistance, type 2 diabetes mellitus (T2DM), hypertension, hyperlipidaemia, and metabolic syndrome (Younossi, 2019; Lazarus et al., 2022b; Adams et al., 2017; Anstee et al., 2013).”
BackgroundIruzubieta, P., de Vega, T., & Crespo, J. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00226-2 · Cited by 20
Self-citationResearch Priorities for Precision Medicine in NAFLD
Iruzubieta, P., Bataller, R. A., Arias, M., Arrese, M. A., Calleja, J. L., Castro‐Narro, G., Cusi, K. J., Dillon, J. F., Martínez‐Chantar, M. L., Mateo, M., et al. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.016 · Cited by 20
Self-citationCircadian rhythms and inflammatory diseases of the liver and gut
Ferrell, J. M. (2023) · Liver Research · doi:10.1016/j.livres.2023.08.004 · Cited by 22
Sepehrinia, M., Khanmohammadi, S., Rezaei, N., & Kuchay, M. S. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.11.032 · Cited by 18
The Effect of Obesity on Gastrointestinal Disease
Shay, J. E. S., & Singh, A. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.008 · Cited by 18
The importance of patient engagement in the multimodal treatment of MASLD
Boeckmans, J., Hagström, H., Cryer, D. R. H., & Schattenberg, J. M. (2025) · Communications Medicine · doi:10.1038/s43856-025-00871-1 · Cited by 19
“Sharing prognostic details on MASLD can engage patients and encourage the introduction and maintenance of behavioral changes 9,60 .”
Self-citationLazure, P., Tomlinson, J., Kowdley, K. V., Magni, P., Santos, R. D., Jacobs, G., & Murray, S. (2022) · Liver International · doi:10.1111/liv.15324 · Cited by 18
“…of proposed models of multidisciplinary practice is beyond the limits of this discussion, a model of care has been developed in a recent review by Lazarus et al. (2021).34 In addition, others have considered how this model can be applied to encourage individual patient behaviour changes, as well…”
MethodGruzdev, S., Podoprigora, I. V., & Gizinger, O. A. (2024) · Archives of Microbiology · doi:10.1007/s00203-023-03752-0 · Cited by 17
Brodosi, L., Stecchi, M., Musio, A., Bazzocchi, M., Risi, E., Marchignoli, F., Marchesini, G., & Petroni, M. L. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02287-0 · Cited by 17
“…of the risks associated with MASLD has been largely documented in the literature [43], and is a matter of concern for dedicated healthcare professionals, requiring intensive approach [44] and prompting the publication of dedicated guidelines for patients [45] and a global priority agenda [46].”
BackgroundSelf-citationKumar, A., Arora, A., Choudhury, A. K., Arora, V., Rela, M., Jothimani, D. K., Mahtab, M. A., Devarbhavi, H. C., Eapen, C. E., Goel, A., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002951 · Cited by 19
Self-citationEmerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao, C. H. E. N., Zhou, Y., Hao, H., & XIONG, J. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60690-4 · Cited by 23
Attacking the public health crisis of hepatocellular carcinoma at its roots
Lee, H. M., Lidofsky, S. D., Taddei, T. H., & Townshend‐Bulson, L. (2022) · Hepatology · doi:10.1002/hep.32741 · Cited by 17
“Such a plan should empower health practitioners with a comprehensive model of care that includes pathways for screening and diagnosis as well as risk stratification tools to guide specialty referral.[16] The plan should also include robust support to promote lifestyle interventions that reduce NAFLD progression and co…”
BackgroundPADs and NETs in digestive system: From physiology to pathology
Song, Y., Wang, Z., Kang, L., He, Z., Zhao, S., Fang, X., Li, Z., Wang, S., & Bai, Y. Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1077041 · Cited by 19
Macrophages in metaflammation – fueling chronic inflammation in metabolic disease
Kardinal, R., & Wachten, D. (2025) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-025-03141-0 · Cited by 16
Applying an equity lens to liver health and research in Europe
Cots, M. V., Bataller, R., Lazarus, J. V., Benach, J., & Pericàs, J. M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.021 · Cited by 16
Self-citationComparison of effects of HucMSCs, exosomes, and conditioned medium on NASH
Liang, C., Gao, S., Gao, J., Xu, Y., & Li, Q. (2023) · Scientific Reports · doi:10.1038/s41598-023-45828-3 · Cited by 18
The double roles of T cell-mediated immune response in the progression of MASLD
Li, Z., Wang, S., Xu, Q., Su, X., Wang, Y., Wang, L., & Zhang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116333 · Cited by 19
Yan, J. Y., Zhou, J. F., Ding, Y., & Tu, C. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1340453 · Cited by 16
“Non-alcoholic fatty liver disease (NAFLD) is a potentially dangerous condition that affects approximately one in four individuals worldwide, leading to a substantial burden of ill health (1, 2).”
BackgroundJaffar, H. M., Ain, H. B. U., Tufail, T., Hanif, A., & Malik, T. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4348 · Cited by 16
“A group of liver diseases known as NAFLD are typified by lipid buildup, which damages the liver and raises enzyme levels (Kumar et al., 2020 ; Lazarus et al., 2022 ; Pafili & Roden, 2021 ).”
BackgroundYeh, M., Huang, J., Dai, C., Huang, C., Yu, M., & Chuang, W. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2388790 · Cited by 16
“Moreover, there is a huge gap in the disease awareness of MASLD, from patients, health-care providers to society groups and policy makers [17,18].”
Self-citationThe anti-inflammatory effect of Pien Tze Huang in non-alcoholic fatty liver disease
Lian, B., Cai, L., Zhang, Z., Fen, L., Li, Z., Zhang, X.-K., & Jiang, F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113076 · Cited by 18
The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting
Thrift, A. P., Nguyen, T. H.-A., Pham, C., Balakrishnan, M., Kanwal, F., Loomba, R. S., Duong, H. T., Ramsey, D. J., & El‐Serag, H. B. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.046 · Cited by 18
Self-citationApproach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Self-citationYu, P., Qian, Z., Yang, H., Xu, T., Dai, Y., Song, L., Liang, J., Shi, Y., Zhang, Z., & Li, L. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175378 · Cited by 16
Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease
Gagnon, É., Manikpurage, H. D., Mitchell, P. L., Girard, A. S., Gobeil, É., Bourgault, J., Bégin, F., Marette, A., Thériault, S., & Arsenault, B. J. (2023) · iScience · doi:10.1016/j.isci.2023.107127 · Cited by 17
“The prevalence of NAFLD and its associated sequelae has been increasing for the past decades, posing a serious threat to global population health.(3) NAFLD is characterized by an accumulation of lipids within hepatocytes (> 5% of hepatocyte mass).”
BackgroundSuárez, M., Martínez, R., Torres, A., Torres, B., & Mateo, J. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08031-y · Cited by 17
“There are even proposal at global level to face this epidemic [39].”
BackgroundRocha, S., Santos, I., Corvo, M. L., Fernandes, E. G. R., & Freitas, M. (2025) · Food & Function · doi:10.1039/d4fo06329e · Cited by 17
Pina, A. F., Meneses, M. J., Ribeiro, R. T., Raposo, J. F., & Macedo, M. P. (2022) · Liver International · doi:10.1111/liv.15406 · Cited by 15
Self-citationHepatic steatosis using ultrasound-derived fat fraction: First technical and clinical evaluation
Huang, Y., Cheng, J., Wang, Y., Xu, X., Wang, S., Li, W., & Dong, Y. (2023) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-238102 · Cited by 18
“Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately 25% of the adult population worldwide [1].”
Kim, H., Lee, S., Jeong, C., Han, Y., & Lee, M. (2024) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13432 · Cited by 15
“The expression of ROR α in type 2b muscle fi bres was slightly reduced in myosteatotic muscle but was restored when the symptoms of myosteatosis were improved ( Figures 1C and 6A ).”
BackgroundInfluentialMetabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology
Zhou, X., Targher, G., Byrne, C. D., Shapiro, M. D., Chen, L.-L., & Zheng, M. (2024) · Cardiology Plus · doi:10.1097/cp9.0000000000000106 · Cited by 15
Self-citationYan, L.-S., Kang, J.-Y., Gu, C.-Y., Qiu, X., Li, J., Cheng, B. C., Wang, Y., Luo, G., & Zhang, Y. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119801 · Cited by 16
Bertran, L., Eigbefoh-Addeh, A., Portillo-Carrasquer, M., Barrientos‐Riosalido, A., Binetti, J., Aguilar, C., Chicote, J. U., Bartra, H., Artigas, L., Coma, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061315 · Cited by 16
“NAFLD is the most prevalent chronic liver disease, with a global prevalence in adults between 23–25% [5,6].”
BackgroundLiver diseases: Perspective from the Philippines
Ornos, E. D. B., Murillo, K. J., & Ong, J. P. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101085 · Cited by 18
Self-citationYao, M., Zhou, P., Qin, Y.-Y., Wang, L., & Yao, D. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1765 · Cited by 17
Pais, R., Cariou, B., Noureddin, M., Francque, S., Schattenberg, J. M., Abdelmalek, M. F., Lalazar, G., Varma, S., Dietrich, J., Miller, V., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.014 · Cited by 15
Self-citationHypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?
Janota, B., Szczepańska, E., Adamek, B., & Janczewska, E. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i5.641 · Cited by 15
Bae, J. H. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0562 · Cited by 15
“Addressing racial and ethnic disparities in MASLD outcomes requires a precision medicine approach that considers the unique genetic, environmental, and social factors affecting different populations 15 .”
BackgroundDanpanichkul, P., Souza, M., Tothanarungroj, P., Ahmed, A., & Kim, D. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0444 · Cited by 15
Lin, Y., Wu, C.-C., Li, Y.-E., Chen, C., Lin, C.-R., & Ni, Y. (2025) · BMC Microbiology · doi:10.1186/s12866-025-03849-0 · Cited by 14
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Allen, A. M., Lazarus, J. V., Alkhouri, N., Noureddin, M., Wong, V. W., Tsochatzis, E. A., de Avila, L., Racila, A., Nader, F., Mark, H. E., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000678 · Cited by 16
“[1,2] 8] The World Health Organization identifies these diseases as the ninth leading cause of death in lower – middle-income countries.”
Self-citationKravchuk, S., Bychkov, M. A., Kozyk, M., Strubchevska, O., & Kozyk, A. (2025) · Cureus · doi:10.7759/cureus.84803 · Cited by 21
“Many patients with hepatic steatosis remain undiagnosed, mainly because the disease has no specific symptoms, and knowledge of MASLD remains poor among non-hepatology and gastroenterology specialists [31].”
Metadata
- Authors
- Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., Francque, S., George, J., Hagström, H., Huang, T. T.-K., Ismail, M. H., Kautz, A., Sarin, S. K., Loomba, R., Miller, V., Newsome, P. N., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gómez, M., Schattenberg, J. M., Tsochatzis, E. A., Valenti, L., Wong, V. W.-S., Yilmaz, Y., Younossi, Z. M., Zelber-Sagi, S., the NAFLD Consensus Consortium, Åberg, F., Adams, L., Khatry, M. S. A., Naamani, K. A., Murillo, O. A., Allen, A. M., Alnaser, F., Alqahtani, S. A., Alswat, K., Alvaro, D., Andrade, R. J., Arrese, M., Awuku, Y. A., Ayesha, M., Baatarkhuu, O., Bakieva, S., Basu, R., Bataller, R., Bedri, S., Bosi, E., Bourliere, M., Bruha, R., Bugianesi, E., Burra, P., Buti, M., Byrne, C. D., Calleja, J. L., Carrieri, P., Carter, F., Fernandez, M. I. C., Castillo-Lopez, G., Castro-Narro, G. E., Chan, H. L. Y., Chan, W.-K., Chang, Y., Colombo, M., Coppell, K. J., Corey, K., Craxi, A., Cryer, D., Dassanayake, A., Martins, A. D. A. S., de Ledinghen, V., DelPrato, S., Demaio, A., Desalegn, H., Dillon, J., Duseja, A., Dorairaj, P., Ekstedt, M., El Kassas, M., Elsanousi, O. M., Esmat, G., Fan, J.-G., Farpour-Lambert, N., Flisiak, R., Fouad, Y., Fuchs, M., Gani, R. A., Gerber, L., Ghazinyan, H., Gheorghe, L., Goh, G. B.-B., Grønbæk, H., Gulnara, A., Hamid, S., Hebditch, V., Hickman, I. J., Hocking, S. L., Hunyady, B., Idilman, R., Isakov, V. A., Jamal, M. H., Jepsen, P., Iskandar, N. J., Song, M. J., Sudhamshu, K. C., Kakizaki, S., Kalamitsis, G., Kanwal, F., Kao, J.-H., Kaplan, L., Kawaguchi, T., Khader, Y., Kim, S. U., Kodjoh, N., Koek, G., Koike, K., Komas, N. P., Korenjak, M., Kugelmas, M., Labidi, A., Lange, N. F., Lavine, J. E., Lazo, M., Lee, N., Lesmana, C. R. A., Liu, C.-J., Long, M. T., Lopez-Jaramillo, P., Malekzadeh, R., Mahtab, M. A., Marchesini, G., Marinho, R., Vázquez, S. E. M., Mateva, L., Nlombi, C. M., Melin, P., Mikolasevic, I., Milovanovic, T., Musso, C., Nakajima, A., Nava, E., Nersesov, A. V., Nikolova, D., Norris, S., Novak, K., Oben, J., Ong, J. P., Onyekwere, C., Papatheodoridis, G., Paruk, I., Patel, K., Macedo, M. P., Penha-Gonçalves, C., Figueroa, M. P., Hofmann, W. P., Petta, S., de Oliveira, C. P. M. S., Puri, P., Pan, C. Q., Rac, M., Ralston, J., Ramji, A., Razavi, H., Alvares-da-Silva, M. R., Roberts, S., Roden, M., Rose, T., Rouabhia, S., Rovere-Querini, P., Rowe, I. A., Sadirova, S., Salupere, R., Saparbu, T., Sayegh, R., Sebastiani, G., Seki, Y., Selmo, J., Serme, A. K., Shaw, J. E., Shenoy, T., Sheron, N., Shibolet, O., Silva, M., Skrypnyk, I., Socha, P., Soriano, J., Spearman, C. W., Sridharan, K., Suárez, J. J., Sheriff, D. S., Sung, K.-C., Swain, M., Tacke, F., Taheri, S., Tan, S.-S., Tapper, E. B., Yki-Järvinen, H., Thiele, M., Shawa, I. T., Tolmane, I., Torres, E. A., Trauner, M., Treeprasertsuk, S., Turcanu, A., Valantinas, J., Vesterhus, M., Waked, I., Wild, S. H., Willemse, J., Wong, R. J., Xanthakos, S., Young, D. Y., Yu, M.-L., Zheng, K. I., Zeybel, M., & Zheng, M.-H.
- Affiliations
- Barcelona Institute for Global Health (ES)
- European Association for the Study of the Liver (CH)
- NIHR Newcastle Biomedical Research Centre (GB)
- Pontificia Universidad Católica de Chile (CL)
- University College London Hospitals NHS Foundation Trust (GB)
- Marqués de Valdecilla University Hospital (ES)
- Veterans Health Administration (US)
- University of Washington (US)
- University of Antwerp (BE)
- The University of Sydney (AU)
- Karolinska Institutet (SE)
- City University of New York (US)
- King Fahd Hospital of the University (SA)
- Institute of Liver and Biliary Sciences (IN)
- University of California San Diego (US)
- University of California, Berkeley (US)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Makerere University (UG)
- Université Paris Cité (FR)
- Northwestern University (US)
- The Graduate Center, CUNY (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- The Royal Free Hospital (GB)
- University of Milan (IT)
- Chinese University of Hong Kong (HK)
- Marmara University (TR)
- Inova Health System (US)
- University of Helsinki (FI)
- The University of Western Australia (AU)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- King Saud University (SA)
- Sapienza University of Rome (IT)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- University of Health and Allied Sciences (GH)
- University of KwaZulu-Natal (ZA)
- Mongolian National University of Medical Sciences (MN)
- Ministry of Health of the Republic of Uzbekistan (UZ)
- University of Virginia (US)
- University of Pittsburgh (US)
- Ahfad University for Women (SD)
- Vita-Salute San Raffaele University (IT)
- University of Turin (IT)
- University of Padua (IT)
- University of Southampton (GB)
- Inserm (FR)
- University of the West Indies (BS)
- Universidad de Buenos Aires (AR)
- Union Hospital (HK)
- University of Malaya (MY)
- Kangbuk Samsung Hospital (KR)
- IRCCS Ospedale San Raffaele (IT)
- University of Otago (NZ)
- Harvard University (US)
- University of Kelaniya (LK)
- University of Pisa (IT)
- St. Paul's Hospital Millennium Medical College (ET)
- University of Dundee (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- World Heart Federation (CH)
- Linköping University (SE)
- National Ribat University (SD)
- Cairo University hospitals (EG)
- Shanghai Jiao Tong University (CN)
- Medical University of Białystok (PL)
- Minia University (EG)
- Virginia Commonwealth University (US)
- University of Indonesia (ID)
- Carol Davila University of Medicine and Pharmacy (RO)
- Singapore General Hospital (SG)
- Aarhus University Hospital (DK)
- Aga Khan University (PK)
- British Liver Trust (GB)
- Princess Alexandra Hospital (AU)
- Kuwait University (KW)
- Hlabisa Hospital (ZA)
- Catholic University of Korea (KR)
- National Academy of Medical Sciences (NP)
- National Hospital Organization Takasaki General Medical Center (JP)
- Baylor College of Medicine (US)
- National Taiwan University Hospital (TW)
- Kurume University (JP)
- Jordan University of Science and Technology (JO)
- Yonsei University (KR)
- Université d'Abomey-Calavi (BJ)
- Maastricht University Medical Centre (NL)
- The University of Tokyo (JP)
- Institut Pasteur de Bangui (CF)
- Denver Public Library (US)
- Hôpital La Rabta (TN)
- University Hospital of Bern (CH)
- Columbia University (US)
- Drexel University (US)
- Wilton Park (GB)
- Boston University (US)
- University of Tehran (IR)
- Bangladesh Medical University (BD)
- University of Bologna (IT)
- Centro Hospitalar Lisboa Norte (PT)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University Hospital St. Ivan Rilski (BG)
- University of Kinshasa (CD)
- Favaloro Foundation (AR)
- Yokohama City University (JP)
- Universidad Autónoma de Nuevo León (MX)
- Ss. Cyril and Methodius University in Skopje (MK)
- St. James's Hospital (IE)
- Ljubljana University Medical Centre (SI)
- Guy's Hospital (GB)
- University of the Philippines Manila (PH)
- Lagos State University (NG)
- National and Kapodistrian University of Athens (GR)
- University Health Network (CA)
- Universidade Nova de Lisboa (PT)
- University of Palermo (IT)
- NYU Langone Health (US)
- World Obesity Federation (GB)
- University of British Columbia (CA)
- Center for Disease Analysis (US)
- Alfred Health (AU)
- Düsseldorf University Hospital (DE)
- University of Leeds (GB)
- Tartu University Hospital (EE)
- Kyrgyz State Medical Academy (KG)
- Saint Joseph University (LB)
- McGill University Health Centre (CA)
- Yotsuya Medical Cube (JP)
- Baker Heart and Diabetes Institute (AU)
- King's College London (GB)
- Tel Aviv University (IL)
- Children's Memorial Health Institute (PL)
- Hospital Universitario de La Princesa (ES)
- University of Cape Town (ZA)
- Arabian Gulf University (BH)
- Universidad San Francisco de Quito (EC)
- University of Calgary (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Weill Cornell Medical College in Qatar (QA)
- Hospital Selayang (MY)
- University of Michigan (US)
- University of Southern Denmark (DK)
- University of Malawi (MW)
- Riga East University Hospital (LV)
- University of Puerto Rico, Medical Sciences Campus (PR)
- Medical University of Vienna (AT)
- Chulalongkorn University (TH)
- Nicolae Testemițanu State University of Medicine and Pharmacy (MD)
- Vilnius University Hospital Santariskiu Klinikos (LT)
- Haraldsplass Diakonale Sykehus (NO)
- National Liver Institute (EG)
- University of Edinburgh (GB)
- Stanford Medicine (US)
- Cincinnati Children's Hospital Medical Center (US)
- National University of Singapore (SG)
- Kaohsiung Medical University (TW)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Koç University (TR)
- Corresponding author
- Lazarus, Jeffrey V.
- ORCID
- Lazarus, Jeffrey V.
- Mark, Henry E.
- Anstee, Quentin M.
- Arab, Juan Pablo
- Batterham, Rachel L.
- Castera, Laurent
- Cortez-Pinto, Helena
- Crespo, Javier
- Cusi, Kenneth
- Dirac, M. Ashworth
- Francque, Sven
- George, Jacob
- Hagström, Hannes
- Huang, Terry T.-K.
- Ismail, Mona H.
- Sarin, Shiv Kumar
- Loomba, Rohit
- Miller, Veronica
- Newsome, Philip N.
- Ninburg, Michael
- Ocama, Ponsiano
- Ratziu, Vlad
- Rinella, Mary
- Romero, Diana
- Romero-Gómez, Manuel
- Schattenberg, Jörn M.
- Tsochatzis, Emmanuel A.
- Valenti, Luca
- Wong, Vincent Wai-Sun
- Yilmaz, Yusuf
- Younossi, Zobair M.
- Åberg, Fredrik
- Adams, Leon
- Naamani, Khalid Al
- Allen, Alina M.
- Alqahtani, Saleh A.
- Alswat, Khalid
- Alvaro, Domenico
- Andrade, Raúl J.
- Arrese, Marco
- Awuku, Yaw Asante
- Baatarkhuu, Oidov
- Bakieva, Shokhista
- Basu, Rita
- Bataller, Ramon
- Bedri, Shahinaz
- Bosi, Emanuele
- Bugianesi, Elisabetta
- Burra, Patrizia
- Byrne, Christopher D.
- Carrieri, Patrizia
- Chan, Henry Lik Yuen
- Chan, Wah-Kheong
- Chang, Yoosoo
- Colombo, Massimo
- Coppell, Kirsten J.
- Corey, Kathleen
- Cryer, Donna
- Dassanayake, Anuradha
- Desalegn, Hailemichael
- Dillon, John
- Duseja, Ajay
- Ekstedt, Mattias
- Elsanousi, Osama M.
- Esmat, Gamal
- Fan, Jian-Gao
- Flisiak, Robert
- Fouad, Yasser
- Fuchs, Michael
- Gani, Rino A.
- Gerber, Lynn
- Gheorghe, Liana
- Goh, George Boon-Bee
- Grønbæk, Henning
- Hamid, Saeed
- Hickman, Ingrid J.
- Hocking, Samantha L.
- Jamal, Mohammad H.
- Jepsen, Peter
- Song, Myeong Jun
- Kakizaki, Satoru
- Kanwal, Fasiha
- Kao, Jia-Horng
- Kaplan, Lee
- Kawaguchi, Takumi
- Khader, Yousef
- Kim, Seung Up
- Kodjoh, Nicolas
- Koek, Ger
- Koike, Kazuhiko
- Komas, Narcisse Patrice
- Korenjak, Marko
- Kugelmas, Marcelo
- Labidi, Asma
- Lange, Naomi F.
- Lavine, Joel E.
- Lazo, Mariana
- Lee, Nancy
- Lesmana, Cosmas Rinaldi A.
- Liu, Chun-Jen
- Long, Michelle T.
- Malekzadeh, Reza
- Mahtab, Mamun Al
- Marchesini, Giulio
- Marinho, Rui
- Vázquez, Sophia E. Martínez
- Nlombi, Charles Mbendi
- Musso, Carla
- Nakajima, Atsushi
- Norris, Suzanne
- Oben, Jude
- Ong, Janus P.
- Onyekwere, Charles
- Papatheodoridis, George
- Paruk, Imran
- Patel, Keyur
- Macedo, M. Paula
- Figueroa, Marlene Pérez
- Hofmann, Wolf Peter
- Petta, Salvatore
- Puri, Puneet
- Pan, Calvin Q.
- Ralston, Johanna
- Ramji, Alnoor
- Razavi, Homie
- Roberts, Stuart
- Roden, Michael
- Rowe, Ian A.
- Sadirova, Shakhlo
- Sebastiani, Giada
- Seki, Yosuke
- Shaw, Jonathan E.
- Sheron, Nick
- Shibolet, Oren
- Silva, Marcelo
- Socha, Piotr
- Soriano, Joan
- Spearman, C. Wendy
- Sridharan, Kannan
- Sheriff, Dhastagir Sultan
- Sung, Ki-Chul
- Swain, Mark
- Tacke, Frank
- Taheri, Shahrad
- Tan, Soek-Siam
- Tapper, Elliot B.
- Thiele, Maja
- Shawa, Isaac Thom
- Tolmane, Ieva
- Torres, Esther A.
- Trauner, Michael
- Treeprasertsuk, Sombat
- Turcanu, Adela
- Valantinas, Jonas
- Vesterhus, Mette
- Waked, Imam
- Wild, Sarah H.
- Wong, Robert J.
- Xanthakos, Stavra
- Yu, Ming-Lung
- Zheng, Kenneth I.
- Zheng, Ming-Hua
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2021-10-27
- Volume
- 19
- Issue
- 1
- Pages
- 60-78
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3208129759
- Cited by
- 757
- References
- 193
- Citations by year
- 2026: 100 · 2025: 156 · 2024: 163 · 2023: 201 · 2022: 127 · 2021: 9
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Falk Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- City University of New York
- Medpace
- Regeneron Pharmaceuticals
- European Federation of Pharmaceutical Industries and Associations
- Arrowhead Pharmaceuticals
- Medicines Company
- Galecto
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Coherus Biosciences
- National Institute for Health and Care Research (RP-2015-06-005)
- Rosetrees Trust
- Novo Nordisk
- Astellas Pharma
- Shionogi
- European Association for the Study of the Liver
- Novo Nordisk Fonden (NNF18OC0054612)
- Servier
- Julius Clinical
- Genentech
- Allergan
- Novartis Pharma
- Takeda Pharmaceuticals International
- Sanofi-Aventis Deutschland
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, public health policy, global health agenda, metabolic syndrome, non-communicable diseases, obesity, health system response, Delphi consensus
- MeSH terms
- Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.